BioNTech’s Personalized mRNA Vaccine Shows 4-Year Immune Response, Phase 2 Trial Underway
BioNTech’s Genentech-partnered personalized mRNA vaccine autogene cevumeran elicited immune responses persisting nearly four years in a Phase 1 pancreatic cancer trial, with responders showing delayed tumor recurrence. A global Phase 2 pancreatic cancer study is now enrolling, while mRNA programs for colorectal cancer and melanoma advance.
1. Autogene Cevumeran Phase 1 Results
BioNTech’s personalized mRNA vaccine autogene cevumeran demonstrated durable immune responses for up to nearly four years in a Phase 1 pancreatic cancer trial at Memorial Sloan Kettering. Patients who responded to the vaccine exhibited delayed tumor recurrence compared with nonresponders, underscoring its potential as a long-term therapeutic strategy.
2. Phase 2 Pancreatic Cancer Trial Enrollment
Following promising Phase 1 data, a larger global Phase 2 trial of autogene cevumeran in pancreatic cancer is now enrolling patients at multiple sites worldwide. This study aims to assess safety, immunogenicity and efficacy endpoints, with interim results anticipated later this year.
3. Colorectal and Melanoma mRNA Programs
BioNTech is also advancing mRNA vaccine candidates for colorectal cancer and melanoma, currently in early-stage clinical testing. These programs trail leading competitors in oncology timelines but leverage the same platform technology validated by autogene cevumeran’s long-term responses.